Biogen Gets EU Nod for First Postpartum Depression Drug

Biogen has received European Commission approval for Zurzuvae (zuranolone) to treat postpartum depression (PPD) in adults, establishing it as the first and only approved PPD treatment in the EU. This follows strong Phase III SKYLARK study results demonstrating rapid and sustained symptom relief. The drug has already shown significant commercial traction in the U.S., with Q2 2025 sales reaching $46.4 million, a 68% sequential increase that exceeded Biogen's internal expectations, positioning Zurzuvae as a key contributor to the company's long-term growth strategy.

Analysis

Biogen has secured a critical regulatory victory with the European Commission's approval of Zurzuvae for postpartum depression (PPD), establishing it as the first and only approved treatment for this indication in the European Union. This milestone opens up a significant, largely untapped market, as Biogen estimates PPD affects 20% of women with recent pregnancies in the region. The approval is substantiated by strong Phase III SKYLARK study data demonstrating rapid and sustained symptom relief. More importantly, this regulatory success is complemented by strong early commercial performance in the United States, where Q2 2025 sales reached $46.4 million, a 68% sequential increase that surpassed the company's internal expectations. This performance provides tangible validation for Zurzuvae's revenue potential, positioning it as a key pillar in Biogen's strategy to drive long-term growth alongside other recent launches like Leqembi and Skyclarys. Notably, this positive operational momentum contrasts with the stock's 5% year-to-date decline against an industry that has gained 3%, suggesting the market may not have fully priced in the drug's potential.

Key Decisions for Investors

• Investors should consider the potential for a positive re-rating of Biogen (BIIB), as its year-to-date share price decline appears disconnected from the strong commercial and regulatory momentum of Zurzuvae, evidenced by 68% sequential US sales growth and new EU market exclusivity.
• Upcoming quarterly reports should be monitored closely for initial sales figures from the EU launch and continued US demand, as these metrics will be critical for validating Zurzuvae's trajectory toward becoming a major revenue contributor.
• Given the partnership structure where Supernus Pharmaceuticals (SUPN) receives royalties from ex-US sales, investors could consider SUPN as a derivative way to gain exposure to Zurzuvae's European success.
• Despite the positive catalyst, the stock's underperformance and Zacks' #3 (Hold) rank suggest caution; weigh the specific potential of Zurzuvae against broader execution risks across Biogen's entire new product portfolio.